Navigation Links
HIV Prevention through Abstinence-only Programs

Abstinence-only programs help to reduce sexual activities among young teens as well as delay first sexual encounters without interfering in future condom use, according// to a recent study of the controversial HIV prevention strategy. The study was conducted on 662 African-American Grade 6 and 7 students from inner-city middle schools in Philadelphia and it was found that those who were taught an abstinence-only approach to sex had lower chances of having had sexual intercourse at 24 months' follow-up compared to those put through a "safer sex" intervention which only emphasized condom use without mentioning abstinence.

Bill Clinton, the former U.S. president, told delegates to the International AIDS Conference in Toronto yesterday that abstinence programs appeared to delay sexual activity while making teens less likely to use condoms when they do start having sex However the study found that the opposite was true.

Lead author John Jemmott, of the University of Pennsylvania, said "It did not reduce intentions to use condoms, it did not reduce beliefs about the efficacy of condoms, it did not decrease consistent condom use and it did not decrease condom use at last sexual [encounter]."

The study was conducted on teens ranging from ages 10 to 15 with half of them being girls. Twenty-three per cent of the youngsters said that they had had sexual intercourse at least once before the study began.

Mr. Jemmott said, "There aren't any studies that show that children are less likely to use condoms as a result of an abstinence intervention. I've looked in the literature; there are no studies that show that. But you have to be concerned about it, because many abstinence-only until marriage programs give misinformation about condoms and present the failure rates in a way that would discourage people from using them."

Planned Parenthood has called the approach "one of the religious right's greatest challenges to the nation's sex
'"/>




Page: 1 2

Related medicine news :

1. Prevention is better than cure
2. Prevention of cataracts
3. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
4. Simple Stroke Prevention is Best
5. Prevention of Prostate Cancer
6. Prevention of Rickets
7. Prevention of Vision Loss
8. Suicide Prevention Program – Having its Intended Effec
9. The Key To Prevention Of Heart Disease In Adults
10. Stroke Prevention
11. Prevention Of Recurrent Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: HIV Prevention through Abstinence only Programs

(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... the Mid-Atlantic region, is the recipient of three awards in the Service Industry ... communications programs created for Choptank Transport, KRM Development Corporation and University of Maryland ...
(Date:7/30/2015)... ... July 30, 2015 , ... Well-known San Diego AC, ... family-owned low cost service and repair companies. For 35 years, they have grown ... their company to meet the demands of the changing technological environment. ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 24/7 Care ... Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid ... system of home health care providers. 24/7 Care At Home’s agency is one of ...
(Date:7/30/2015)... Dallas, TX (PRWEB) , ... July 30, 2015 ... ... Experience Grant Program and fourth annual Institute Scholar Program. In partnership with Patient ... field of patient experience, develop leaders on the front lines and throughout the ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3
... , WASHINGTON, Aug. 12 "The opposition ... major financial stakes in the status quo," say former Chief ... Policy spokesman Bob Weiner and Analyst Jordan Osserman in a ... "30 key lawmakers involved in health legislation total $11 ...
... ... allows you to most accurately determine the longitude, latitude and altitude ... This multi-perspective triangulation clearly leads to precise objective measurements. In a ... of key vital signs from all stakeholders to assist you in ...
... ... pill has been associated with numerous warnings. If YAZ®/Yasmin® side effects have ... ... 12, 2009 -- The widely-used oral contraceptive YAZ® (alternatively named Yasmin® ) has recently ...
... NASHVILLE, Tenn., Aug. 11 Emdeon Inc. (the "Company") ... shares of its Class A common stock at a price of ... by the Company and 12,975,000 were offered by selling stockholders. The ... the ticker symbol "EM." To the extent that the underwriters sell ...
... , , , ... to repay more than $500 million in benefits that were unlawfully ... part of a class action settlement preliminarily approved by U.S. District ... were suspended or denied between 2000 and 2006 will be notified ...
... , , , ... WST ) today announced that William Federici, Chief Financial Officer, and ... attending the Ninth Annual CJS Securities "New Ideas" Summer Conference on Tuesday, ... While there will be no formal presentation or a webcast, Mr. ...
Cached Medicine News:Health News:Health Care Opposition Exposed; Ex-White House Drug Spokesman Bob Weiner and Analyst Jordan Osserman Tell of 'Web of Vested Interests' 2Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 2Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 3Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 2Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 3Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 4Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 2Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 3Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 4Health News:Government Stops Unlawful Social Security Suspensions; Agrees to Repay More Than Half a Billion in Back Benefits 2
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Wash., Aug. 30 SCOLR Pharma, Inc. (NYSE AMEX: ... agreement with The Emerson Group to provide sales support for ... products. The Emerson Group ( www.emersongroup.com ), ... that provides strategic consulting and sales execution services to companies ...
... Inc., the world leader in PyroCarbon orthopedic devices, announces ... in the United Kingdom. The PyroTITAN was implanted at ... Lennard Funk, BSc MBBCh MSc FRCS(Tr&Orth), the ... active and independent but could no longer play golf ...
Cached Medicine Technology:SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products 2SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products 3Ascension Orthopedics Implants First PyroCarbon Shoulder Device in United Kingdom 2
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
... are available in 14 configurations including the ... Microgenics Antibody Technology, the SureStep™ MDMA (Ecstasy) ... immunoassay targeted to detect MDMA that has ... but no cross-reactivity to any isomer of ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
... is a quantitative microplate enzyme immunoassay that can ... for rapid recurrence or occult disease. The test ... and is twice as sensitive as urine cytology. ... outcome by identifying those patients who may benefit ...
Medicine Products: